ArticleFrontiers in oncology2019
Development and Validation of an IDH1-Associated Immune Prognostic Signature for Diffuse Lower-Grade Glioma.
Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 50 citations in OpenAlex.
- TFAP2D drives neuroblastoma progression: a disulfidptosis-fatty acid metabolism-based molecular subtyping and prognostic model.Translational pediatrics · 2026Article
- NSUN5/TET2-directed chromatin-associated RNA modification of 5-methylcytosine to 5-hydroxymethylcytosine governs glioma immune evasion.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Article
- ToPP: Tumor online prognostic analysis platform for prognostic feature selection and clinical patient subgroup selection.iScience · 2022Article
- A 1p/19q Codeletion-Associated Immune Signature for Predicting Lower Grade Glioma Prognosis.Cellular and molecular neurobiology · 2022Article
- Identification of a Nomogram with an Autophagy-Related Risk Signature for Survival Prediction in Patients with Glioma.International journal of general medicine · 2022Article
- Identification of Implications of Angiogenesis and m6A Modification on Immunosuppression and Therapeutic Sensitivity in Low-Grade Glioma by Network Computational Analysis of Subtypes and Signatures.Frontiers in immunology · 2022Article
- Weighted Gene Coexpression Network Analysis Identifies TBC1D10C as a New Prognostic Biomarker for Breast Cancer.Analytical cellular pathology (Amsterdam) · 2022Article
- Uncovering the Immune Cell Infiltration Landscape in Low-Grade Glioma for Aiding Immunotherapy.Journal of oncology · 2022Article
- Development and Validation of a Novel Prognostic Model for Lower-Grade Glioma Based on Enhancer RNA-Regulated Prognostic Genes.Frontiers in oncology · 2022Article
- A Risk Score Signature Consisting of Six Immune Genes Predicts Overall Survival in Patients with Lower-Grade Gliomas.Computational and mathematical methods in medicine · 2022Article
- Mutational profiling of low-grade gliomas identifies prognosis and immunotherapy-related biomarkers and tumour immune microenvironment characteristics.Journal of cellular and molecular medicine · 2021Article
- Dysregulation of tumor microenvironment promotes malignant progression and predicts risk of metastasis in bladder cancer.Annals of translational medicine · 2021Article
- Development and Validation of a Radiosensitivity Prediction Model for Lower Grade Glioma Based on Spike-and-Slab Lasso.Frontiers in oncology · 2021Article
- Development of a Prognostic Five-Gene Signature for Diffuse Lower-Grade Glioma Patients.Frontiers in neurology · 2021Article
- DNA Methylation-Driven Genes for Developing Survival Nomogram for Low-Grade Glioma.Frontiers in oncology · 2021Article
- Development and validation of a VHL-associated immune prognostic signature for clear cell renal cell carcinoma.Cancer cell international · 2020Article
- Dissecting Molecular Features of Gliomas: Genetic Loci and Validated Biomarkers.International journal of molecular sciences · 2020Review
- Identification of a three-long noncoding RNA prognostic model involved competitive endogenous RNA in kidney renal clear cell carcinoma.Cancer cell international · 2020Article
- Dysregulation of the Immune Microenvironment Contributes to Malignant Progression and Has Prognostic Value in Bladder Cancer.Frontiers in oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A mutation in the isocitrate dehydrogenase 1 (IDH1) gene is the most common mutation in diffuse lower-grade gliomas (LGGs), and it is significantly related to the prognosis of LGGs. We aimed to explore the influence of the IDH1 mutation on the immune microenvironment and develop an IDH1-associated immune prognostic signature (IPS) for predicting prognosis in LGGs. IDH1 mutation status and RNA expression were investigated in two different public cohorts. To develop an IPS, LASSO Cox analysis was conducted for immune-related genes that were differentially expressed between IDH1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.